Journal of clinical anesthesia · 2025
Myocardial injury and short- and long-term outcomes after oncological surgery: A large-scale retrospective cohort study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Shaoyong, Song Xiong, Li Yi, Huang Jingxiu, Ke Xiao, Feng Chenyang, Xing Wei, Cao Fei, Zeng Weian
Аннотация
BACKGROUND: Myocardial injury after noncardiac surgery (MINS) significantly contributes to perioperative mortality, yet its incidence and prognostic value in patients undergoing oncological surgery remain inadequately characterized.
METHODS: In this retrospective cohort study, we analyzed 6277 adults (mean age 58.9 years; 60.0 % male) undergoing intermediate-to-high-risk oncological surgeries between September 2013 and September 2022 with postoperative high-sensitivity troponin I (hsTnI) measurements. Dose-response relationships between peak hsTnI and the outcomes of 30-day mortality and 30-day major adverse cardiovascular events (MACE) were modeled using multivariable Cox regression with restricted cubic splines. MINS was defined as an ischemic hsTnI elevation >26 ng/L. Long-term (365-day) mortality was analyzed using both 30-day landmark analysis and flexible parametric survival model (FPSM) to account for potential time-varying effects.
RESULTS: Each standard deviation increase in log-transformed hsTnI was associated with a twofold higher risk of 30-day mortality (adjusted hazard ratio [aHR] 2.33, 95 % CI: 1.94-2.80; P < 0.001) and a nearly fourfold higher risk of 30-day MACE (aHR 3.91, 95 % CI: 3.47-4.42; P < 0.001). After excluding 22 patients with nonischemic troponin elevations, MINS occurred in 19.1 % of patients, with 98.7 % being asymptomatic. MINS independently predicted 30-day mortality (aHR 7.10, 95 % CI: 4.21-11.97; P < 0.001) and accounted for 53.8 % of the population-attributable risk. Adding MINS modestly improved the C-index for 30-day mortality prediction (0.831 vs. 0.797; ΔC-index, 0.034; P = 0.090) but significantly improved risk reclassification (net reclassification improvement, 31.51 %) and discrimination (integrated discrimination improvement, 0.037). Landmark analysis showed an 8.1-fold increased risk within 30 days and a sustained 1.8-fold risk from day 31 to 365. FPSM confirmed a sustained excess mortality hazard throughout the year.
CONCLUSIONS: MINS is common, largely asymptomatic, and strongly associated with both early and late mortality after oncological surgery. Routine troponin monitoring may help identify high-risk patients for intervention.
METHODS: In this retrospective cohort study, we analyzed 6277 adults (mean age 58.9 years; 60.0 % male) undergoing intermediate-to-high-risk oncological surgeries between September 2013 and September 2022 with postoperative high-sensitivity troponin I (hsTnI) measurements. Dose-response relationships between peak hsTnI and the outcomes of 30-day mortality and 30-day major adverse cardiovascular events (MACE) were modeled using multivariable Cox regression with restricted cubic splines. MINS was defined as an ischemic hsTnI elevation >26 ng/L. Long-term (365-day) mortality was analyzed using both 30-day landmark analysis and flexible parametric survival model (FPSM) to account for potential time-varying effects.
RESULTS: Each standard deviation increase in log-transformed hsTnI was associated with a twofold higher risk of 30-day mortality (adjusted hazard ratio [aHR] 2.33, 95 % CI: 1.94-2.80; P < 0.001) and a nearly fourfold higher risk of 30-day MACE (aHR 3.91, 95 % CI: 3.47-4.42; P < 0.001). After excluding 22 patients with nonischemic troponin elevations, MINS occurred in 19.1 % of patients, with 98.7 % being asymptomatic. MINS independently predicted 30-day mortality (aHR 7.10, 95 % CI: 4.21-11.97; P < 0.001) and accounted for 53.8 % of the population-attributable risk. Adding MINS modestly improved the C-index for 30-day mortality prediction (0.831 vs. 0.797; ΔC-index, 0.034; P = 0.090) but significantly improved risk reclassification (net reclassification improvement, 31.51 %) and discrimination (integrated discrimination improvement, 0.037). Landmark analysis showed an 8.1-fold increased risk within 30 days and a sustained 1.8-fold risk from day 31 to 365. FPSM confirmed a sustained excess mortality hazard throughout the year.
CONCLUSIONS: MINS is common, largely asymptomatic, and strongly associated with both early and late mortality after oncological surgery. Routine troponin monitoring may help identify high-risk patients for intervention.